Nuveen Asset Management LLC Has $26 Million Stock Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Posted by on Mar 2nd, 2023

Nuveen Asset Management LLC trimmed its position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Get Rating) by 12.5% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 558,724 shares of the biopharmaceutical company’s stock after selling 79,874 shares during the quarter. Nuveen Asset Management LLC owned approximately 0.59% of Intra-Cellular Therapies worth $25,997,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in ITCI. JPMorgan Chase & Co. boosted its stake in shares of Intra-Cellular Therapies by 11.7% during the first quarter. JPMorgan Chase & Co. now owns 157,144 shares of the biopharmaceutical company’s stock valued at $9,615,000 after purchasing an additional 16,454 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Intra-Cellular Therapies by 5.2% during the first quarter. Bank of New York Mellon Corp now owns 385,508 shares of the biopharmaceutical company’s stock valued at $23,591,000 after purchasing an additional 18,999 shares in the last quarter. Cambridge Investment Research Advisors Inc. acquired a new stake in shares of Intra-Cellular Therapies during the first quarter valued at about $349,000. PNC Financial Services Group Inc. boosted its stake in shares of Intra-Cellular Therapies by 25.6% during the first quarter. PNC Financial Services Group Inc. now owns 5,909 shares of the biopharmaceutical company’s stock valued at $363,000 after purchasing an additional 1,204 shares in the last quarter. Finally, Natixis Advisors L.P. boosted its stake in shares of Intra-Cellular Therapies by 71.3% during the first quarter. Natixis Advisors L.P. now owns 18,165 shares of the biopharmaceutical company’s stock valued at $1,112,000 after purchasing an additional 7,558 shares in the last quarter. 86.95% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on ITCI shares. Cantor Fitzgerald reissued an “overweight” rating and set a $83.00 price target on shares of Intra-Cellular Therapies in a research note on Wednesday, February 1st. Canaccord Genuity Group raised their price objective on Intra-Cellular Therapies from $90.00 to $93.00 in a research report on Friday, November 4th. StockNews.com upgraded Intra-Cellular Therapies from a “sell” rating to a “hold” rating in a research report on Friday, November 4th. Finally, Needham & Company LLC restated a “buy” rating and set a $70.00 price objective on shares of Intra-Cellular Therapies in a research report on Wednesday. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, Intra-Cellular Therapies has an average rating of “Moderate Buy” and an average price target of $71.38.

Insiders Place Their Bets

In other Intra-Cellular Therapies news, CEO Sharon Mates sold 33,083 shares of Intra-Cellular Therapies stock in a transaction that occurred on Tuesday, December 13th. The stock was sold at an average price of $55.00, for a total value of $1,819,565.00. Following the completion of the sale, the chief executive officer now directly owns 1,100,309 shares in the company, valued at $60,516,995. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other news, SVP Suresh K. Durgam sold 8,354 shares of the business’s stock in a transaction that occurred on Tuesday, February 21st. The stock was sold at an average price of $46.84, for a total transaction of $391,301.36. Following the completion of the sale, the senior vice president now owns 23,104 shares in the company, valued at $1,082,191.36. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Sharon Mates sold 33,083 shares of the business’s stock in a transaction that occurred on Tuesday, December 13th. The shares were sold at an average price of $55.00, for a total value of $1,819,565.00. Following the sale, the chief executive officer now owns 1,100,309 shares of the company’s stock, valued at approximately $60,516,995. The disclosure for this sale can be found here. Over the last three months, insiders sold 184,591 shares of company stock worth $9,106,853. 3.70% of the stock is owned by corporate insiders.

Intra-Cellular Therapies Stock Performance

Shares of ITCI stock opened at $49.32 on Thursday. The company has a market cap of $4.67 billion, a P/E ratio of -14.86 and a beta of 1.10. The stock has a 50 day simple moving average of $49.23 and a two-hundred day simple moving average of $49.53. Intra-Cellular Therapies, Inc. has a fifty-two week low of $42.42 and a fifty-two week high of $66.00.

Intra-Cellular Therapies Company Profile

(Get Rating)

Intra-Cellular Therapies, Inc operates as a biopharmaceutical company. It focuses on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS.

Featured Articles

Institutional Ownership by Quarter for Intra-Cellular Therapies (NASDAQ:ITCI)

Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.